Integrated Analysis of High-Resolution Gene Expression and Copy Number Profiling Identified Biallelic Deletion of CDKN2A/2BTumor Suppressor Locus As the Most Frequent and Unique Genomic Abnormality in Diffuse Large B-Cell Lymphoma (DLBCL) with Strong Prognostic Value in Both GCB and ABC Subtypes and Not Overcome by a Dose-Intensive Immunochemotherapy Regimen Plus Rituximab. Results of a Prospective GELA Clinical Trial Program

MLA

Jardin, Fabrice, et al. “Integrated Analysis of High-Resolution Gene Expression and Copy Number Profiling Identified Biallelic Deletion of CDKN2A/2BTumor Suppressor Locus As the Most Frequent and Unique Genomic Abnormality in Diffuse Large B-Cell Lymphoma (DLBCL) with Strong Prognostic Value in Both GCB and ABC Subtypes and Not Overcome by a Dose-Intensive Immunochemotherapy Regimen Plus Rituximab. Results of a Prospective GELA Clinical Trial Program.” Blood, vol. 120, no. 21, Nov. 2012, p. 415. EBSCOhost, https://doi.org/10.1182/blood.V120.21.415.415.

APA

Jardin, F., Mareschal, S., Figeac, M., Jais, J.-P., Leroy, K., Copie-Bergman, C., Salles, G. A., Coiffier, B., Delarue, R., Peyrade, F., Bosly, A., Ketterer, N., Haioun, C., Tilly, H., & Molina, T. J. (2012). Integrated Analysis of High-Resolution Gene Expression and Copy Number Profiling Identified Biallelic Deletion of CDKN2A/2BTumor Suppressor Locus As the Most Frequent and Unique Genomic Abnormality in Diffuse Large B-Cell Lymphoma (DLBCL) with Strong Prognostic Value in Both GCB and ABC Subtypes and Not Overcome by a Dose-Intensive Immunochemotherapy Regimen Plus Rituximab. Results of a Prospective GELA Clinical Trial Program. Blood, 120(21), 415. https://doi.org/10.1182/blood.V120.21.415.415

Chicago

Jardin, Fabrice, Sylvain Mareschal, Martin Figeac, Jean-Philippe Jais, Karen Leroy, Christiane Copie-Bergman, Gilles Andre Salles, et al. 2012. “Integrated Analysis of High-Resolution Gene Expression and Copy Number Profiling Identified Biallelic Deletion of CDKN2A/2BTumor Suppressor Locus As the Most Frequent and Unique Genomic Abnormality in Diffuse Large B-Cell Lymphoma (DLBCL) with Strong Prognostic Value in Both GCB and ABC Subtypes and Not Overcome by a Dose-Intensive Immunochemotherapy Regimen Plus Rituximab. Results of a Prospective GELA Clinical Trial Program.” Blood 120 (21): 415. doi:10.1182/blood.V120.21.415.415.